TY - JOUR
T1 - Value and Cost of Myeloma Therapy
AU - Rajkumar, S. Vincent
PY - 2018/5/23
Y1 - 2018/5/23
N2 - Major advances have occurred in the treatment of multiple myeloma, including several new drugs that typically cost more than $100,000 per year. Although the gains in myeloma therapy improve overall survival considerably, they are available to only a fraction of the population of patients with myeloma in the world because of regulatory barriers and cost. Myeloma is an example of what is happening in cancer on a much larger scale. Many of the problems discussed call for a wider discussion across all cancers, but they are amplified in myeloma because of the need for multidrug regimens that combine three or more expensive new drugs for prolonged periods of time. In this article, the reasons for the high cost of cancer drugs and possible solutions are examined. The lack of correlation of value and price, the remarkable rise in prices of existing old medications over time, and the lack of access to lifesaving drugs across various countries are also discussed.
AB - Major advances have occurred in the treatment of multiple myeloma, including several new drugs that typically cost more than $100,000 per year. Although the gains in myeloma therapy improve overall survival considerably, they are available to only a fraction of the population of patients with myeloma in the world because of regulatory barriers and cost. Myeloma is an example of what is happening in cancer on a much larger scale. Many of the problems discussed call for a wider discussion across all cancers, but they are amplified in myeloma because of the need for multidrug regimens that combine three or more expensive new drugs for prolonged periods of time. In this article, the reasons for the high cost of cancer drugs and possible solutions are examined. The lack of correlation of value and price, the remarkable rise in prices of existing old medications over time, and the lack of access to lifesaving drugs across various countries are also discussed.
UR - http://www.scopus.com/inward/record.url?scp=85056075491&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85056075491&partnerID=8YFLogxK
U2 - 10.1200/EDBK_200867
DO - 10.1200/EDBK_200867
M3 - Review article
C2 - 30231405
AN - SCOPUS:85056075491
SN - 1548-8756
SP - 662
EP - 666
JO - American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
JF - American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
IS - 38
ER -